Cadence Design Systems Inc., through its Cadence Molecular Sciences (OpenEye) business unit, has partnered with Treeline Biosciences to develop and validate ROCS X, an AI-driven virtual screening platform for drug discovery. This collaboration enabled the creation of ROCS X, which allows scientists to conduct 3D searches across trillions of drug-like molecules-vastly expanding the scale of chemical space that can be explored for potential therapeutics. Treeline Biosciences used ROCS X to identify and physically source over 150 novel, synthesizable compounds as drug candidates, accelerating their efforts to address serious medical conditions such as cancer. Early access to ROCS X is now available, with general availability expected in the first quarter of 2026.